Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664482 · ClinicalTrials.gov registry record · NA
A Single-Patient Study Using AGS 006
A NA study, sponsored by Argos Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00664482 is a NA study that has completed, run by Argos Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT00664482, a NA study, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
Interventions
- BIOLOGICAL AGS-006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00664482
The ClinicalTrials.gov registry entry for NCT00664482 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Argos Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AGS-006 is the first listed.
NCT00664482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00664482 about?
NCT00664482 is a clinical study titled "A Single-Patient Study Using AGS 006". Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
What is the current status of trial NCT00664482?
This trial is currently completed. It is a NA study. The enrollment target is 1 participants. The study started on 2007-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00664482?
The interventions under investigation include: AGS-006 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00664482?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.